Literature DB >> 9872386

Downregulation of fibronectin transcription in highly metastatic adenocarcinoma cells.

S E Werbajh1, A J Urtreger, L I Puricelli, E S de Lustig, E Bal de Kier Joffé, A R Kornblihtt.   

Abstract

Silencing of fibronectin (FN) expression seems to be one of the key mechanisms underlying metastatic behaviour. An inverse correlation exists between FN expression levels and the metastatic potential of two related murine mammary adenocarcinomas, M3 and MM3. Primary cultures of M3 tumour, which is moderately metastatic to lung (40% incidence), show a conspicuous FN extracellular matrix (ECM) and high levels of FN mRNA, while primary cultures of the highly metastatic MM3 tumour (95% lung incidence) are negative for FN in immunofluorescence and show at least 40-fold lower levels of FN mRNA, only detectable by RT-PCR, with a different pattern of alternatively spliced EDI isoforms compared to M3 cells. We show that the FN promoter sequence is not altered in MM3 cells. Transfection experiments with CAT constructs indicate that silencing occurs at the transcriptional level, involving the 220-bp proximal promoter region.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9872386     DOI: 10.1016/s0014-5793(98)01473-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells.

Authors:  Lorena Rodriguez; Alcira Batlle; Gabriela Di Venosa; Sinan Battah; Paul Dobbin; Alexander J Macrobert; Adriana Casas
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

2.  KSHV regulation of fibulin-2 in Kaposi's sarcoma: implications for tumorigenesis.

Authors:  Donald J Alcendor; Susan Knobel; Prashant Desai; Wen Qui Zhu; Gary S Hayward
Journal:  Am J Pathol       Date:  2011-07-07       Impact factor: 4.307

3.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.

Authors:  J A Aguirre-Ghiso; D Liu; A Mignatti; K Kovalski; L Ossowski
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

4.  Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy.

Authors:  Adriana Casas; Gabriela Di Venosa; Silvia Vanzulli; Christian Perotti; Leandro Mamome; Lorena Rodriguez; Marina Simian; Angeles Juarranz; Osvaldo Pontiggia; Tayyaba Hasan; Alcira Batlle
Journal:  Cancer Lett       Date:  2008-07-26       Impact factor: 8.679

5.  Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin.

Authors:  Cristian A Droppelmann; Jaime Gutiérrez; Cecilia Vial; Enrique Brandan
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

6.  A mathematical model for the onset of avascular tumor growth in response to the loss of p53 function.

Authors:  Howard A Levine; Michael W Smiley; Anna L Tucker; Marit Nilsen-Hamilton
Journal:  Cancer Inform       Date:  2007-02-17

7.  Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies.

Authors:  C Perotti; H Fukuda; G DiVenosa; A J MacRobert; A Batlle; A Casas
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

8.  Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression.

Authors:  S L White; S Gharbi; M F Bertani; H-L Chan; M D Waterfield; J F Timms
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

9.  Mechanistic studies on delta-aminolevulinic acid uptake and efflux in a mammary adenocarcinoma cell line.

Authors:  S Correa García; A Casas; C Perotti; A Batlle; M Bermúdez Moretti
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

10.  Delta-Aminolevulinic acid transport in murine mammary adenocarcinoma cells is mediated by beta transporters.

Authors:  M Bermúdez Moretti; S Correa García; C Perotti; A Batlle; A Casas
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.